The ProMetic Life Sciences Inc. (PLI) Receives “Outperform” Rating from Scotiabank

The ProMetic Life Sciences Inc. (PLI) Receives “Outperform” Rating from Scotiabank

Scotiabank restated their outperform rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research note released on Thursday morning. The firm currently has a C$5.00 price objective on the stock.

A number of other equities research analysts have also issued reports on PLI. Royal Bank Of Canada reiterated an outperform rating on shares of ProMetic Life Sciences in a research note on Wednesday, June 15th. CIBC lowered their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Finally, TD Securities reiterated a speculative buy rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research note on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of C$4.84.

ProMetic Life Sciences (TSE:PLI) remained flat at $3.09 during midday trading on Thursday. The company had a trading volume of 298,417 shares. The stock has a 50 day moving average of $2.92 and a 200-day moving average of $3.01. ProMetic Life Sciences has a 1-year low of $1.67 and a 1-year high of $3.62. The company’s market capitalization is $1.87 billion.

Related posts

Leave a Comment